The ultimate goal of this proposal is to understand the role of innate immunity within the context of oncolytic viral (OV) therapy for glioblastoma multiforme (GBM). OV treatment of GBM relies on cancer-specific replication of the virus leading to tumor destruction with minimal toxicity to adjacent non-neoplastic tissue. Results from the 5 clinical trials in patients with malignant glioma have shown the relative safety of this novel treatment modality. However, evidence for significant efficacy remains to be established. Our attention in this project focuses on the natural killer (NK) cell response following viral administration. Due to their antiviral properties, NK cells represent a potential barrier to OV therapy. Alternatively, the antitumor NK response has the potential of augmenting the tumor clearing properties of OV therapy. Our previously published rat in vivo studies have demonstrated that 1) the inflammatory response mediated by activated macrophages/microglia limit OV efficacy and 2) transient immune modulation with cyclophosphamide significantly enhances GBM clearance following OV inoculation. As a result, we hypothesize that NK cells coordinate a robust inflammatory response following initial OV administration that limits viral replication, spread, and tumor lysis, thereby creating a barrier to effective OV therapy for GBM. In this project, we will determine: a) how the antiviral and antitumor properties of NK cells impact overall OV therapeutic efficacy for GBM;b) how NK cells mediate macrophage/microglia inflammatory polarization;c) the key mechanistic signals that lead to NK mediated clearance of OV-infected glioma;and d) how pharmacological agents such as cyclophosphamide and valproic acid modulate the NK response following OV treatment, leading to enhanced clearance of GBM. By elucidating the role of NK cells in orchestrating the inflammatory response following OV therapy, we are highlighting a critical therapeutic target that, when hiodulated, will potentially enhance OV efficacy for GBM. Moreover, the significance of our experiments extends beyond virotherapy into the realm of virology and immunology as we attempt to discern the key mechanistic signals leading to NK mediated clearance of viral infection.
Despite decades of research, prognosis for patients suffering from malignant glioblastoma multiforme (GBM) remains poor. Oncolytic viral (OV) therapy is an experimental treatment currently being evaluated in clinical trials for efficacy against GBM;however, the initial host immune response has been demonstrated to impede OV efficacy. The proposed basic research will investigate a potential barrier to this efficacy, natural killer cells, that can likely be modulated to enhance OV clinical efficacy for malignant GBM.
|Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183|
|Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4|
|Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572|
|Kim, Yangjin; Yoo, Ji Young; Lee, Tae Jin et al. (2018) Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci U S A 115:4927-4932|
|Sadahiro, Hirokazu; Kang, Kyung-Don; Gibson, Justin T et al. (2018) Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. Cancer Res 78:3002-3013|
|Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804|
|Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787|
|Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208|
|Marzulli, M; Mazzacurati, L; Zhang, M et al. (2018) A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors. J Gene Ther 3:|
|Russell, Luke; Swanner, Jessica; Jaime-Ramirez, Alena Cristina et al. (2018) PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance. Nat Commun 9:5006|
Showing the most recent 10 out of 117 publications